Charles Schwab’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.66M | Sell |
113,374
-1,025
| -0.9% | -$15.2K | ﹤0.01% | 2847 |
|
|
2026
Q1 | $1.66M | Buy |
114,399
+8,102
| +8% | +$94K | ﹤0.01% | 2765 |
|
|
2025
Q4 | $1.02M | Buy |
106,297
+2,427
| +2% | +$23.2K | ﹤0.01% | 2920 |
|
|
2025
Q3 | $976K | Sell |
103,870
-29,177
| -22% | -$279K | ﹤0.01% | 2960 |
|
|
2025
Q2 | $1.41M | Sell |
133,047
-16,888
| -11% | -$213K | ﹤0.01% | 2782 |
|
|
2025
Q1 | $2.25M | Buy |
149,935
+12,473
| +9% | +$207K | ﹤0.01% | 2573 |
|
|
2024
Q4 | $2.26M | Sell |
137,462
-12,494
| -8% | -$246K | ﹤0.01% | 2636 |
|
|
2024
Q3 | $3.7M | Sell |
149,956
-188
| -0.1% | -$4.87K | ﹤0.01% | 2512 |
|
|
2024
Q2 | $3.8M | Buy |
150,144
+3,776
| +3% | +$97.9K | ﹤0.01% | 2474 |
|
|
2024
Q1 | $3.72M | Buy |
146,368
+28,211
| +24% | +$683K | ﹤0.01% | 2394 |
|
|
2023
Q4 | $2.68M | Buy |
118,157
+4,546
| +4% | +$94.1K | ﹤0.01% | 2527 |
|
|
2023
Q3 | $2.12M | Buy |
113,611
+1,362
| +1% | +$28.2K | ﹤0.01% | 2577 |
|
|
2023
Q2 | $2.92M | Buy |
112,249
+1,750
| +2% | +$46.8K | ﹤0.01% | 2436 |
|
|
2023
Q1 | $3.17M | Sell |
110,499
-660
| -0.6% | -$19.6K | ﹤0.01% | 2393 |
|
|
2022
Q4 | $3.29M | Buy |
111,159
+2,152
| +2% | +$61.2K | ﹤0.01% | 2402 |
|
|
2022
Q3 | $2.6M | Buy |
109,007
+4,935
| +5% | +$114K | ﹤0.01% | 2507 |
|
|
2022
Q2 | $2.32M | Sell |
104,072
-78
| -0.1% | -$1.74K | ﹤0.01% | 2525 |
|
|
2022
Q1 | $2.62M | Buy |
104,150
+2,580
| +3% | +$78.7K | ﹤0.01% | 2551 |
|
|
2021
Q4 | $3.64M | Buy |
101,570
+5
| +0% | +$200 | ﹤0.01% | 2512 |
|
|
2021
Q3 | $4.32M | Buy |
101,565
+1,917
| +2% | +$79K | ﹤0.01% | 2443 |
|
|
2021
Q2 | $4.31M | Sell |
99,648
-18,919
| -16% | -$806K | ﹤0.01% | 2422 |
|
|
2021
Q1 | $4.84M | Buy |
118,567
+5,016
| +4% | +$190K | ﹤0.01% | 2317 |
|
|
2020
Q4 | $5.14M | Buy |
113,551
+120
| +0.1% | +$4.55K | ﹤0.01% | 2197 |
|
|
2020
Q3 | $4.01M | Sell |
113,431
-317
| -0.3% | -$11.4K | ﹤0.01% | 2182 |
|
|
2020
Q2 | $4.29M | Sell |
113,748
-1,790
| -2% | -$59K | ﹤0.01% | 2098 |
|
|
2020
Q1 | $3.34M | Sell |
115,538
-5,428
| -4% | -$220K | ﹤0.01% | 2038 |
|
|
2019
Q4 | $6.27M | Buy |
120,966
+3,179
| +3% | +$185K | ﹤0.01% | 1905 |
|
|
2019
Q3 | $6.47M | Buy |
117,787
+23,943
| +26% | +$1.23M | ﹤0.01% | 1838 |
|
|
2019
Q2 | $3.81M | Buy |
93,844
+12,895
| +16% | +$470K | ﹤0.01% | 2106 |
|
|
2019
Q1 | $2.45M | Buy |
80,949
+3,552
| +5% | +$122K | ﹤0.01% | 2296 |
|
|
2018
Q4 | $2.6M | Sell |
77,397
-4,946
| -6% | -$179K | ﹤0.01% | 2225 |
|
|
2018
Q3 | $3.47M | Buy |
82,343
+3,414
| +4% | +$135K | ﹤0.01% | 2234 |
|
|
2018
Q2 | $2.53M | Buy |
78,929
+2,544
| +3% | +$105K | ﹤0.01% | 2301 |
|
|
2018
Q1 | $3.8M | Buy |
76,385
+7,834
| +11% | +$443K | ﹤0.01% | 2078 |
|
|
2017
Q4 | $3.7M | Buy |
68,551
+2,686
| +4% | +$149K | ﹤0.01% | 2070 |
|
|
2017
Q3 | $3.82M | Sell |
65,865
-4,414
| -6% | -$231K | ﹤0.01% | 2019 |
|
|
2017
Q2 | $3.47M | Buy |
70,279
+5,436
| +8% | +$250K | ﹤0.01% | 2004 |
|
|
2017
Q1 | $2.82M | Buy |
64,843
+3,408
| +6% | +$163K | ﹤0.01% | 2056 |
|
|
2016
Q4 | $3.01M | Buy |
61,435
+9,818
| +19% | +$454K | ﹤0.01% | 1998 |
|
|
2016
Q3 | $2.47M | Buy |
51,617
+25,111
| +95% | +$1.24M | ﹤0.01% | 2037 |
|
|
2016
Q2 | $1.42M | Hold |
26,506
| – | – | ﹤0.01% | 2219 |
|
|
2016
Q1 | $1.19M | Sell |
26,506
-75,900
| -74% | -$3.08M | ﹤0.01% | 2274 |
|
|
2015
Q4 | $3.91M | Sell |
102,406
-5,253
| -5% | -$201K | 0.01% | 1685 |
|
|
2015
Q3 | $3.43M | Sell |
107,659
-41,417
| -28% | -$1.44M | 0.01% | 1727 |
|
|
2015
Q2 | $4.92M | Hold |
149,076
| – | – | 0.01% | 1551 |
|
|
2015
Q1 | $6.14M | Hold |
149,076
| – | – | 0.01% | 1357 |
|
|
2014
Q4 | $6.07M | Buy |
149,076
+33,962
| +30% | +$1.33M | 0.01% | 1292 |
|
|
2014
Q3 | $4.22M | Buy |
115,114
+11,404
| +11% | +$493K | 0.01% | 1515 |
|
|
2014
Q2 | $4.8M | Sell |
103,710
-39,320
| -27% | -$1.75M | 0.01% | 1429 |
|
|
2014
Q1 | $5.88M | Buy |
143,030
+3,500
| +3% | +$130K | 0.01% | 1203 |
|
|
2013
Q4 | $5.33M | Buy |
139,530
+14,600
| +12% | +$450K | 0.01% | 1201 |
|
|
2013
Q3 | $3.11M | Buy |
124,930
+108,730
| +671% | +$2.44M | 0.01% | 1552 |
|
|
2013
Q2 | $281K | Buy |
+16,200
| New | +$234K | ﹤0.01% | 2754 |
|
Other funds holding ANIK
CP
BFM
CM
Charles Schwab's ANIK Position: Q2 2026 in Review
Charles Schwab reduced its Anika Therapeutics (ANIK) stake by 0.9% in Q2 2026, selling an estimated $15.2K and leaving 113,374 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2847.
Charles Schwab first reported a position in ANIK in Q2 2013 and has held it in 53 quarters since. The position peaked at $6.47M in Q3 2019. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.
- Charles Schwab held 113,374 shares of Anika Therapeutics worth $1.66M as of Q2 2026.
- Charles Schwab sold 1,025 Anika Therapeutics shares in Q2 2026, an estimated $15.2K.
- Anika Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2847 holding.
- Charles Schwab first reported a position in Anika Therapeutics in Q2 2013 and has held it in 53 quarters since.
- Charles Schwab's Anika Therapeutics position peaked at $6.47M in Q3 2019.
- 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.